Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 250

Similar articles for PubMed (Select 17114665)

1.

Aromatase inhibitors and bone health in women with breast cancer.

Chien AJ, Goss PE.

J Clin Oncol. 2006 Nov 20;24(33):5305-12. Review. No abstract available.

PMID:
17114665
2.

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.

3.

Bone density in breast cancer: when to intervene?

Gralow JR.

J Clin Oncol. 2007 Aug 1;25(22):3194-7. Epub 2007 Jun 18. No abstract available.

4.

The bone substudy of MA.27: does bone make a difference?

Mathew A, Brufsky A.

Lancet Oncol. 2014 Apr;15(4):375-7. doi: 10.1016/S1470-2045(14)70050-6. Epub 2014 Mar 11. No abstract available.

PMID:
24636209
5.

Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.

Freedman OC, Verma S, Clemons MJ.

Breast Cancer Res Treat. 2006 Oct;99(3):241-7. Epub 2006 Jun 3. Review.

PMID:
16752075
6.

Impact of aromatase inhibitors on bone health in breast cancer patients.

Geisler J, L√łnning PE.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):294-9. doi: 10.1016/j.jsbmb.2009.10.004. Epub 2009 Oct 13.

PMID:
19833206
7.

Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.

Berruti A, Tucci M, Mosca A, Vana F, Ardine M, Dogliotti L, Angeli A, Bertoldo F.

J Clin Oncol. 2007 Apr 10;25(11):1455-6. No abstract available.

8.

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.

Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.

PMID:
17618847
9.

Women and bone health: maximizing the benefits of aromatase inhibitor therapy.

Tang SC.

Oncology. 2010;79(1-2):13-26. doi: 10.1159/000314997. Epub 2010 Nov 3. Review.

PMID:
21051913
10.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA; Z-FAST and ZO-FAST Study Groups.

Oncologist. 2008 May;13(5):503-14. doi: 10.1634/theoncologist.2007-0206.

11.

Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.

Aapro M.

Anticancer Drugs. 2008 Mar;19 Suppl 2:S1. doi: 10.1097/01.cad.0000277610.08129.06. No abstract available.

PMID:
18337639
12.

[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].

Forciniti S.

Suppl Tumori. 2004 Jul-Aug;3(4):S25-6. Italian. No abstract available.

PMID:
15206205
13.

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE.

Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2.

PMID:
18515009
14.

[Effect of aromatase inhibitors on bone metabolism].

Folkestad L, Bjerregaard JK, Bjarnason NH, Brixen KT.

Ugeskr Laeger. 2007 May 7;169(19):1774-9. Review. Danish.

PMID:
17537350
15.

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.

Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Review. Dutch.

PMID:
17319217
16.

Current developments in hormonal therapy of breast cancer.

Buzdar AU.

Clin Breast Cancer. 2004 Sep;5 Suppl 1:S4-5. Review. No abstract available.

PMID:
15347432
17.
18.

[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].

Gori S, Anastasi P, Marrocolo F.

Suppl Tumori. 2004 Jul-Aug;3(4):S27-31. Italian. No abstract available.

PMID:
15206206
19.

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.

Markopoulos C.

Breast Cancer Res. 2010;12(4):403. doi: 10.1186/bcr2609. Epub 2010 Aug 3. No abstract available.

20.

[For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].

Jonat W.

MMW Fortschr Med. 2006 Mar 23;148(12):10. German. No abstract available.

PMID:
16625996
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk